Compare SID & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | GLPG |
|---|---|---|
| Founded | 1941 | 1999 |
| Country | Brazil | Belgium |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1997 | 2005 |
| Metric | SID | GLPG |
|---|---|---|
| Price | $1.86 | $33.01 |
| Analyst Decision | Strong Sell | Hold |
| Analyst Count | 1 | 4 |
| Target Price | $1.40 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 3.0M | 99.7K |
| Earning Date | 11-04-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,522,708,358.00 | $336,643,201.00 |
| Revenue This Year | $4.93 | $1.76 |
| Revenue Next Year | N/A | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.02 | ★ 10.31 |
| 52 Week Low | $1.24 | $22.36 |
| 52 Week High | $1.88 | $37.78 |
| Indicator | SID | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 63.56 | 58.80 |
| Support Level | $1.60 | $32.33 |
| Resistance Level | $1.88 | $33.91 |
| Average True Range (ATR) | 0.06 | 0.72 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 88.33 | 62.13 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations in railways and port terminals. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.